Amylin Phase II CHF data

AMLN said that in an open-label U.S. Phase II study in 14 patients with class III or IV congestive heart failure (CHF), its AC2592 infusion improved composite scores designed to quantify quality of life and cardiac function. Outcome measures included peak oxygen consumption, left ventricular ejection fraction, quality of life assessment, and brain natriuretic peptide (BNP). The trial followed patients for 12 weeks, and patients did not receive AC2592 from weeks 10-12. Scores returned to baseline when AC2592 was discontinued. The most common adverse event was mild to moderate nausea. ...